Oral Contraceptives: Effect on Hemostasis

  • Morris Notelovitz
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)

Abstract

A case report in 1961, that associated the taking of an oral contraceptive for the treatment of endometriosis and pulmonary embolism, led to the linkage between sex steroids and abnormalities in hemostasis.1 A series of epidemiologic studies was subsequently published — primarily from the United Kingdom — which supported this initial clinical observation, and it was concluded that women using oral contraceptives were at increased risk for venous thromboembolic disease.2–4 Subsequently, a relationship was also found between oral contraceptive use and other forms of cardiovascular disease, primarily myocardial infarction and stroke.5–7

Keywords

Estrogen Aspirin Neurol Progesterone Smoke 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jordan WM. Pulmonary embolism. Lancet 1961; 2: 1146–1147.CrossRefGoogle Scholar
  2. 2.
    Royal College of General Practitioners. Oral contraception and thrombo-embolic disease. J R Coll Pract 1967; 13: 267–279.Google Scholar
  3. 3.
    Inman WHW, Vessey MP. Investigation of deaths from pulmonary, coronary and cerebral thrombosis and embolism in women of childbearing age. Brit Med J 1968; 2: 193–199.PubMedCrossRefGoogle Scholar
  4. 4.
    Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Brit Med J 1968; 2: 199–205.PubMedCrossRefGoogle Scholar
  5. 5.
    Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. Brit Med J 1975; 2: 241–245.PubMedCrossRefGoogle Scholar
  6. 6.
    Shapiro J, Sloane D, Rosenberg L, et al. Oral contraceptive use in relation to myocardial infarction. Lancet 1979; 1: 743–747.PubMedCrossRefGoogle Scholar
  7. 7.
    Collaborative Group for the Study of Stroke in Young Women. Oral contraceptive and stroke in young women: associated risk factors. JAMA 1975; 231: 718–722.CrossRefGoogle Scholar
  8. 8.
    Stadel BV. Oral contraceptives and cardiovascular disease. Part One. N Engl J Med 1981; 305: 612–618.PubMedCrossRefGoogle Scholar
  9. 9.
    Wessler S, Gitel SN, Wan LS, Pasternack BS. Estrogen-containing oral contraceptive agents: a basis for thrombogenicity. JAMA 1976; 236: 2179–2182.PubMedCrossRefGoogle Scholar
  10. 10.
    Notelovitz M. Oral contraception and coagulation. Clin Obstet Gynecol 1985; 28: 73–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 158: 1646–1652.PubMedGoogle Scholar
  12. 12.
    Gertsman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epid 1991; 133: 32–36.Google Scholar
  13. 13.
    Stampfer MJ, Willet WC, Corditz GA, et al. Past use of oral contraceptives and cardiovascular disease: a meta analysis in the context of the Nurses’ Health Study. Am J Obstet Gynecol 1990; 163: 285–291.PubMedGoogle Scholar
  14. 14.
    Mann JI, Inman WHW, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. Brit Med J 1976; 2: 445–447.PubMedCrossRefGoogle Scholar
  15. 15.
    Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ Oral Contraception Study. Brit Med J 1989; 298: 165–168.PubMedCrossRefGoogle Scholar
  16. 16.
    Mammen EF. Oral Contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142: 781 - 790.PubMedGoogle Scholar
  17. 17.
    Kluft C. Disorders of the hemostatic system and the risk of the development of thrombotic and cardiovascular diseases: limitations of laboratory diagnosis. Am J Obstet Gynecol 1990; 163: 305–312.PubMedGoogle Scholar
  18. 18.
    Kelleher CC. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease. Am J Obstet Gynecol 1990; 163: 392–395.PubMedGoogle Scholar
  19. 19.
    Rick ME. Protein C and protein S. Vitamin-K dependent inhibitors of blood coagulation. JAMA 1990; 263: 701–703.PubMedCrossRefGoogle Scholar
  20. 20.
    Jespersen J, Peterson KR, Skouby SD. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990; 163: 396–403.PubMedGoogle Scholar
  21. 21.
    Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381–387.PubMedGoogle Scholar
  22. 22.
    Lijnen HB, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role of the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255: 10214–10222.PubMedGoogle Scholar
  23. 23.
    Haukkamaa M, Morgan WT, Koskelo P. Serum histidine-rich glycoprotein during pregnancy and hormone treatment. Scand J Clin Lab Invest 1983; 43: 591–595.PubMedCrossRefGoogle Scholar
  24. 24.
    Aoki N, Saito H, Kamiya T, et al. Congenital deficiency of 2 plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877–884.PubMedCrossRefGoogle Scholar
  25. 25.
    Bounameaux H, Cirafici P, de Moerloose P, et al. Measurement of d-dimer in plasma as diagnostic aid inGoogle Scholar
  26. 26.
    George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27–39.PubMedCrossRefGoogle Scholar
  27. 27.
    Oates OJA, Fitzgerald G, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988; 319: 689–698.PubMedCrossRefGoogle Scholar
  28. 28.
    Masotti G, Galanti G, Pogessi L, et al. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet 1979; 2: 1213–1217.PubMedCrossRefGoogle Scholar
  29. 29.
    Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. Obstet Gynecol Surv 1985; 40: 425–436.PubMedCrossRefGoogle Scholar
  30. 30.
    Jespersen J. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. Dan Med Bull 1988; 35: 1–33.PubMedGoogle Scholar
  31. 31.
    Poller L, Thomson JM, Thomas W. Oestrogen/ Progestogen oral contraception and blood clotting: a long-term follow up. Brit Med J 1971; 4: 648–650.PubMedCrossRefGoogle Scholar
  32. 32.
    Poller L, Thomson JM, Tabiono A, et al. Progesterone oral contraception and blood clotting. Br Med J 1969; 1: 554–556.PubMedCrossRefGoogle Scholar
  33. 33.
    Sabra A, Bonner J. Hemostatic system changes induced by 50 mg and 30 mg estrogen/ progestogen oral contraceptives. J Reprod Med 1983; 28 (suppl): 85–91.Google Scholar
  34. 34.
    Melis GB, Fruzzetti F, Ricci C, et al. Oral contraceptives and venous thromboembolic disease: the effect of oestrogen dose. Maturitas 1988; (Suppl 1 ): 131–139.Google Scholar
  35. 35.
    Bottiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; 1: 1097–1101.PubMedCrossRefGoogle Scholar
  36. 36.
    Hirsch J. Hypercoagulability. Semin Thromb-Hemost 1975; 2: 14–32.PubMedGoogle Scholar
  37. 37.
    Tengborn L, Larsson A, Hedner U, et al. Coagulation studies in children and young adults with cerebral ischemic episodes. Acta Neurol Scand 1981; 63: 351–361.PubMedCrossRefGoogle Scholar
  38. 38.
    Bergqvist L, Bergqvist D, Hedner U. Oral contraceptives and venous thromboembolism. Brit J Obstet Gynecol 1982; 89: 381–386.CrossRefGoogle Scholar
  39. 39.
    Von Kaulla E, Droegemueller W, Aoki, et al. Anti-thrombin III depression and thrombin generation acceleration in women taking oral contraceptives. Am J Obstet Gynecol 1971; 109: 868–873.Google Scholar
  40. 40.
    Zuck TF, Bergin JJ. Thrombotic predisposi-tion association with oral contraceptives. Obstet Gynecol 1973; 41: 427–435.PubMedGoogle Scholar
  41. 41.
    Notelovitz M, Kitchens CS, Coone L, et al. Low-dose oral contraceptive usage and coagulation. Am J Obstet Gynecol 1981; 141: 71–75.PubMedGoogle Scholar
  42. 42.
    Gitel SN, Wessler S. Plasma anti-thrombin III — a quantitative assay of biological activity. Thromb Res 1975; 7: 5–16.PubMedCrossRefGoogle Scholar
  43. 43.
    Jespersen J, Ingeberg S, Bach E. Anti-thrombin III and platelets during the normal menstrual cycle and in women receiving oral contraceptives low in oestrogen. Gynecol Obstet Invest 1983; 15: 153–162.PubMedCrossRefGoogle Scholar
  44. 44.
    Weenik GH, Kahle LN, Ten Cate JW, et al. Anti-thrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand 1984; 63: 57–61.CrossRefGoogle Scholar
  45. 45.
    Burkman RT, Bell WR, Zacur HA, et al. Oral contraceptives and anti-thrombin III: variation by dosage and ABO group. Obstet Gynecol 1991; 164: 1453–1460.Google Scholar
  46. 46.
    Jick H, Sloane D, Westerholm B, et al. Venous thromboembolic disease and ABO blood type. Lancet 1969; 1: 539–542.PubMedCrossRefGoogle Scholar
  47. 47.
    Notelovitz M, Kitchens CS, Khan FY. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral con-traceptives: a controlled comparative 12-month clinical trial. Am J Obstet Gynecol 1992; 167 (5): 1225–1261.Google Scholar
  48. 48.
    Conrad J, Samama M, Salomon Y. Anti-thrombin III and the oestrogen content of combined oestrogen-progesteren contraceptives. Lancet 1972; 2: 1148–1149.CrossRefGoogle Scholar
  49. 49.
    Abbate R, Pinto S, Rostagno C, et al. Effects of long-term gestadene-containing oral contraceptive administration on hemostasis. Am J Obstet Gynecol 1990; 163: 424–430.PubMedGoogle Scholar
  50. 50.
    Melis GB, Fruzzetti F, Nicoletti I, et al. A comparative study on the effects of a mono- phasic pill containing desogestrel, plus 20 mg ethinyl estradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception 1991; 43: 23–31.PubMedCrossRefGoogle Scholar
  51. 51.
    Daly L, Bonnar J. Comparative studies of 30 mg ethinyl estradiol combined with gestodene and desogestrol on blood coagulation, fibrinolysis and platelets. Am J Obstet Gynecol 1990; 163: 430–437.PubMedGoogle Scholar
  52. 52.
    Meade TW, Stirling Y, Wilkes H, et al. Effects of oral contraceptives and obesity on protein C antigen. Thromb Haemost 1985; 53: 198–199.PubMedGoogle Scholar
  53. 53.
    Gilabert J, Fernandez JA, Espana F, et al.pected pulmonary embolism. Lancet 1990; i: 196–200. Physiological coagulation inhibitors (protein S, protein C and anti-thrombin III) in severe pre-eclamptic states and in users of oral contraceptives. Thromb Res 1988; 49: 319–329.Google Scholar
  54. 54.
    Farag AM, Bottoms SF, Mammen EF, et al. Oral contraceptives and the hemostatic system. Obstet Gynecol 1988; 71: 584–588.PubMedGoogle Scholar
  55. 55.
    Jespersen J, Nielsen MT. Levels of protein S during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest 1989; 28: 82–86.PubMedCrossRefGoogle Scholar
  56. 56.
    Huisveld IA, Hospers JEH, Meijers JCM, et al. Oral contraceptives reduce total protein S, but not free protein S. Thromb Res 1987; 45: 109–114.PubMedCrossRefGoogle Scholar
  57. 57.
    Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Brit J Haematol 1988; 68: 437–443.CrossRefGoogle Scholar
  58. 58.
    Engesser L, Broekmans AN, Briet E, et al. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106: 677–682.PubMedGoogle Scholar
  59. 59.
    Poller L. Oral contraceptives, blood clotting, and thrombosis. Brit Med Bull 1978; 34: 151–156.PubMedGoogle Scholar
  60. 60.
    Notelovitz M. Progestogens and coagulation. Int Proceed J 1989; 1: 229–234.Google Scholar
  61. 61.
    Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemost 1982; 48: 283–285.PubMedGoogle Scholar
  62. 62.
    Gevers Leuven JA, Kluft C, Bertina RM, et al. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631–636.PubMedGoogle Scholar
  63. 63.
    Jespersen J, Kluft C. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemost 1986; 55: 388–389.PubMedGoogle Scholar
  64. 64.
    Harpel PC. Protease inhibitors — a precarious balance. N Engl J Med 1983; 309: 725–726.PubMedCrossRefGoogle Scholar
  65. 65.
    Alkjaersig N, Fletcher AP, Burstein R. Association between oral contraceptive use and thromboembolism: a new approach to its investigation based on plasma fibrinogen chromatography. Am J Obstet Gynecol 1975; 122: 199–211.PubMedGoogle Scholar
  66. 66.
    Notelovitz M. Coagulation, oestrogen and the menopause. Clin Obstet Gynecol 1977; 4: 107–128.Google Scholar
  67. 67.
    Zuck TF, Bergin JJ; Raymond JM, et al. Platelet adhesiveness in symptomatic women taking oral contraceptives. Thromb Diath Haemorrh (Stuttgart) 1971; 26: 426–430.Google Scholar
  68. 68.
    Mettler L, Selchow BM. Oral contraceptives and platelet function. Thromb Diath Haemorrh (Stuttgart) 1972; 28: 213–220.Google Scholar
  69. 69.
    Caspary EA, Perbedy M. Oral contraception and blood platelet adhesiveness. Lancet 1965; 1: 1142–1145.PubMedCrossRefGoogle Scholar
  70. 70.
    Adams JH, Mitchell JR, Soppitt GD. Effect of oral contraceptives on lipoprotein activity and platelet stickiness. Lancet 1970; 2: 333–335.PubMedCrossRefGoogle Scholar
  71. 71.
    Bierenbaum ML, Fleischman AI, Stier A, et al. Increased platelet aggregation and decreased high density lipoprotein cholesterol in women on oral contraceptives. Am J Gynecol Obstet 1979; 134: 638–641.Google Scholar
  72. 72.
    Juhan-Vague I, Vague P. Interrelations be-tween carbohydrates, lipids and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease. Am J Obstet Gynecol 1990; 163: 313–315.PubMedGoogle Scholar
  73. 73.
    Vague P, Juhan-Vague I, Alessie MC, et al. Metformin decreases high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57: 326–328.PubMedGoogle Scholar
  74. 74.
    Alessi MC, Juhan-Vague I, Kouistra T, et al. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491–494.PubMedGoogle Scholar
  75. 75.
    Grieninger G, Plant PW, Liang TJ, et al. Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann NY Acad Sei 1983; 408: 469–489.CrossRefGoogle Scholar
  76. 76.
    Mitropoulus KA, Miller GJ, Reaves BEA, et al. Factor VII coagulant activity is strongly associated with plasma concentrations of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203–208.CrossRefGoogle Scholar
  77. 77.
    McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 300: 132–137.CrossRefGoogle Scholar
  78. 78.
    Hamsten A, deFaire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Durrington PN, Ishola M, Hunt L, et al. Apolipoprotein(a) Ax and B and parental history in men with early onset ischemic heart disease. Lancet 1988; 1: 1070–1073.PubMedCrossRefGoogle Scholar
  80. 80.
    Royal College of General Practitioners. Fur-ther analysis of mortality in oral contraceptive users. Lancet 1981; 1: 541–557.Google Scholar
  81. 81.
    Nadler JL, Velasco JS, Horton R. Cigarette smoking inhibits prosterayelin formation. Lancet 1983; 1: 12–48.Google Scholar
  82. 82.
    Notelovitz M, Levenson I, McKenzie L, et al. The effects of low-dose oral contraceptives on coagulations and fibrinolysis in two high risk populations: young female smokers and older premenopausal women. Am J Obstet Gynecol 1985; 152: 995–1000.PubMedGoogle Scholar
  83. 83.
    Hedlin AM, Milojevic S, Korey A. Hemostatic changes induced by exercise during oral contraceptive use. Can J Physiol Pharmacol 1978; 56: 316–326.PubMedCrossRefGoogle Scholar
  84. 84.
    Hedlin AM, Milojevic J, Korey A. Plasminogen activator levels in plasma and urine during exercise and oral contraceptive use. Thromb Haemost (Stuttgart) 1978; 39: 743–750.Google Scholar
  85. 85.
    Notelovitz M, Zauner C, McKenzie L, et al. The effect of low-dose oral contraceptives on cardiorespiratory function, coagulation and lipids in exercising young women: a preliminary report. Am J Obstet Gynecol 1987; 156: 591–598.PubMedGoogle Scholar
  86. 86.
    Huisveld IA, Hospers AJ, Bernink MJ. Oral contraception and fibrinolysis among female cyclists before and after exercise. Appl Physiol 1982; 53: 330–334.Google Scholar
  87. 87.
    Royal College of General Practitioners. Recommendations from the findings of the RCGP and contraception study on the mortality risks of oral contraceptives users. Brit Med J 1972; 2: 947–948.Google Scholar
  88. 88.
    Goldzieher JW, Dozier TS. Oral contraceptives and thromboembolism: a reassessment. Am J Obstet Gynecol 1975; 123: 878–914.PubMedGoogle Scholar
  89. 89.
    Barnes RT, Krapf T, Hoak JC. Erroneous clinical diagnosis of leg vein thrombosis in women on oral contraceptives. Obstet Gynecol 1978; 51: 556–558.PubMedCrossRefGoogle Scholar
  90. 90.
    Upton GV. The contraceptive and hormonal requirements of the premenopausal woman: the years from forty to fifty. Int J Fortic 1985; 30: 44–52.Google Scholar
  91. 91.
    Adam SA, Thorogood M, Mann JL Oral contraception and myocardial infarction revisited: the effects of new preparations and pre-scribing patterns. Brit J Obstet Gynecol 1981; 88: 838–845.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1993

Authors and Affiliations

  • Morris Notelovitz

There are no affiliations available

Personalised recommendations